New York is currently home to 4446 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including New York, Rochester, Bronx and Buffalo. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
The BENeFiTS Trial in Beta Thalassemia Intermedia
Recruiting
Beta-thalassemias and hemoglobinopathies are serious inherited blood diseases caused by abnormal or deficiency of beta A chains of hemoglobin, the protein in red blood cells which delivers oxygen throughout the body.The diseases are characterized by hemolytic anemia, organ damage, and early mortality without treatment. Increases in another type of (normal) hemoglobin, fetal globin (HbF), which is normally silenced in infancy, reduces anemia and morbidity. Even incremental augmentation of fetal g... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Weil Cornell Medicine, New York, New York
Conditions: Beta Thalassemia Intermedia, Sickle Cell Disease
FOXP1 Syndrome: The Seaver Autism Center for Research and Treatment is Characterizing FOXP1-related Neurodevelopmental Disorders Using Genetic, Medical, and Neuropsychological Measures.
Recruiting
FOXP1, also known as Forkhead-box Protein P1, is a transcription factor protein belonging to the FOX gene family. Disruptions in the FOXP1 gene cause a phenotype characterized by global developmental delay, speech deficits, mild dysmorphic features, and traits of autism spectrum disorder. This study seeks to characterize FOXP1-related neurodevelopmental disorders using a number of genetic, medical and neuropsychological measures.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
04/01/2024
Locations: The Seaver Autism Center for Research and Treatment, New York, New York
Conditions: FOXP1, Mental Retardation With Language Impairment and With or Without Autistic Features, Autism Spectrum Disorder
Confirmatory Clinical Evaluation of Novilase® Laser Therapy for Focal Destruction of Malignant Breast Tumors
Recruiting
Prior to this confirmatory pivotal study, the multicenter Br-002 feasibility study was completed. 98% of tumors less than or equal to 15mm were completely ablated in one procedure.This study will evaluate Novilase for the focal destruction of malignant tumors of the breast that are less than or equal to 15 mm against a performance goal for the standard of care, lumpectomy. The ASBrS' goal of less than 20% retreatment by 2020 was selected as a representative performance goal, i.e., 80.0%, and is... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
04/01/2024
Locations: Buffalo General Medical Center, Buffalo, New York
Conditions: Malignant Neoplasm of Breast
Weight Loss Study: Genetics and Response to Naltrexone/Bupropion
Recruiting
The goal of this clinical trial is to understand if genetic variations are associated with the amount of weight loss with diet and while taking an FDA-approved medication for weight loss. The main question\[s\] it aims to answer are: * In Aim One, the investigators propose to rigorously test the hypothesis that presence of the Taq1A A1+ polymorphism is associated with greater weight loss with NB compared with the A1- genotype. * In Aim Two, the investigators will explore other genetic polymorph... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/31/2024
Locations: Columbia University Medical Center, New York, New York
Conditions: Obesity
Comparison of Virtual Pelvic Floor Physical Therapy With a Pelvic Floor Trainer in the Treatment of Stress Urinary Incontinence.
Recruiting
The goal of this clinical trial is to compare the efficacy of the electromyography component of the company's pelvic health product in a patient population with stress urinary incontinence to treatment with pelvic floor physical therapy. The main questions it aims to answer are: Does treatment with the device under study improve symptoms of stress urinary incontinence as measured by the ICIQ when compared to pelvic floor physical therapy? Does treatment with the device under study combined wi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
03/28/2024
Locations: Pelex, Little Neck, New York
Conditions: Stress Urinary Incontinence, Pelvic Floor Disorders
JAGUAR Trial: ObJective Analysis to GaUge EVAR Outcomes Through Randomization
Recruiting
Prospective, randomized, multi-center study designed to evaluate the outcomes of commercially available contemporary EVAR in a real-world population. Patients will be randomized into two device cohorts and compared across the primary endpoints. Patients will be followed procedurally to discharge, at 1, 6, 12 months and annually through to 5 years (total follow-up commitment).
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/28/2024
Locations: Icahn School of Medicine at Mount Sinai, New York, New York
Conditions: AAA, AAA - Abdominal Aortic Aneurysm
Determination and Validation of a Multi-analyte Assay for Lung Cancer Screening
Recruiting
This study is part of the development and validation of a non-invasive lung screening test which aim to identify early stage lung cancer in patients at high risk for lung cancer.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
03/28/2024
Locations: Northwell Health, New Hyde Park, New York
Conditions: Lung Cancer
Intratumoral and Systemic Hiltonol® (Poly-ICLC) in Prostate Cancer Patients on Active Surveillance
Recruiting
This is a partially blinded randomized controlled phase II pilot study comparing Poly-ICLC (Hiltonol®) treatment vs no treatment, for prostate cancer participants on active surveillance.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Icahn School of Medicine at Mount Sinai (ISMMS), New York, New York
Conditions: Prostate Cancer Patients on Active Surveillance
Tau Biomarkers in Late-onset Psychosis (LOP)
Recruiting
Hallucinations or delusions that occur for the first time in older people with no acute medical problems or mood symptoms may be related to impending dementia. This study aims to confirm this hypothesis using novel blood biomarkers and Positron Emission Tomography (PET) imaging tracers, as well as non-invasive testing.
Gender:
ALL
Ages:
Between 65 years and 85 years
Trial Updated:
03/27/2024
Locations: The Feinstein Institutes for Medical Research, Manhasset, New York
Conditions: Late Onset Schizophrenia, Delusional Disorder (Late Onset)
Pediatric Percutaneous Ultrasound Gastrostomy Technique
Recruiting
The purpose of this research study is to test a new device called the PUMA-G Pediatric System. The research will measure if the device works well to safely aid doctors placing gastrostomy feeding tubes in children. The PUMA-G Pediatric System is an investigational device that uses ultrasound and magnets to guide insertion of a feeding tube.
Gender:
ALL
Ages:
Between 0 years and 21 years
Trial Updated:
03/27/2024
Locations: Nyph/Cumc, New York, New York
Conditions: Gastrostomy, Gastrostomy Complications, Pediatric Disorder, Ultrasound
Cold Agglutinin Disease Real World Evidence Registry
Recruiting
This is a multinational, multi-center, observational, prospective, longitudinal disease registry designed to collect data on participants with cold agglutinin disease (CAD) or cold agglutinin syndrome (CAS). Among them, a minimum of 30 patients with CAD treated with sutimlimab are expected to take part in the sutimlimab cohort study. Patients with CAD who have been enrolled in previous sutimlimab clinical trials (e.g., BIVV009-01/LTS16214 \[NCT02502903,CAD patients\], BIVV009-03/EFC16215 \[NCT03... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Northwell Health-Monter Cancer Center-North Shore University Hospital and Steven and Alexandra Cohen Children's Medical Center of New York (Schneider Children's Hospital)-North Shore Long Island Jewis Site Number : 1231, Lake Success, New York
Conditions: Cold Agglutinin Disease (CAD), Cold Agglutinin Syndrome (CAS)
64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
Recruiting
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Weill Cornell Medicine at New York-Presbyterian, New York, New York
Conditions: Prostatic Neoplasms, Castration-Resistant